ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ADC Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11161
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ADC Therapeutics SA (ADCT) is a pharmaceutical company that develops a pipeline of proprietary antibody drug conjugates for the treatment of both solid and hematological cancers. The company offers combining monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine -based warheads to selectively kill cancer cells. It conducts research on next-generation cancer biologic therapies. ADCT targets a wide range of cancers such as breast lung, prostate, renal, blood cancer, and others. The company has exclusive technology license partnership with Spirogen for the development of PBD-based Antibody-Drug-Conjugates. It also has corporate partnerships with MedImmune, Cancer Research Technology, Genmab, and others. ADCT is headquartered in Lausanne, Switzerland.

ADC Therapeutics SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
Private Equity 14
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
Partnerships 15
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
Licensing Agreements 20
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
Equity Offering 29
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA – Key Competitors 32
ADC Therapeutics SA – Key Employees 33
ADC Therapeutics SA – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Product Approvals 35
Jun 09, 2017: ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma 35
Clinical Trials 36
Apr 13, 2018: Promising pre-clinical data supporting BerGenBios pipeline to be published and presented at upcoming leading conferences 36
Apr 11, 2018: ADC Therapeutics to Present New Investigational Antibody-Drug Conjugate ADCT-601 at the American Association for Cancer Research (AACR) Annual Meeting 37
Apr 11, 2018: ADC Therapeutics to Present on its Lymphoid Malignancies Drug Candidate DCT-301 at the American Association for Cancer Research (AACR) Annual Meeting 38
Dec 11, 2017: ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301 39
Dec 11, 2017: ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402 41
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data for ADCT-402 at American Society of Hematology 2017 Annual Meeting 43
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data on ADCT-301 at the American Society of Hematology 2017 Annual Meeting 44
Jun 16, 2017: ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma 45
Jun 16, 2017: ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA, Key Competitors 32
ADC Therapeutics SA, Key Employees 33
ADC Therapeutics SA, Other Locations 34

List of Figures
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Eisai Inc:企業のM&A・事業提携・投資動向
    Eisai Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eisai Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Applied Maths NV:医療機器:M&Aディール及び事業提携情報
    Summary Applied Maths NV (Applied Maths), a subsidiary of bioMerieux SA, is a bioinformatics company that designs, develops and markets bioscience software products. The company offers software products such as bionumerics, gelcompar II, bionumerics server and bionumerics calculation engine. Its bio …
  • First Electric Cooperative Corporation:企業の発電所・SWOT分析2018
    First Electric Cooperative Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informati …
  • RCR Tomlinson Ltd (RCR):企業の財務・戦略的SWOT分析
    RCR Tomlinson Ltd (RCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報
    Summary Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise aging and regenerative medicine, cancer biology, immune system biology, metabolism and diabetes, neuroscience and neurological disorders, …
  • Jubilant Life Sciences Ltd (JUBILANT):製薬・医療:M&Aディール及び事業提携情報
    Summary Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company’s product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical …
  • AccentCare Inc:企業の戦略的SWOT分析
    AccentCare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Georgetown University:製薬・医療:M&Aディール及び事業提携情報
    Summary Georgetown University (GU) is an academic and research institute that offers educational services. The university provides undergraduate and graduate degree programs in the fields of law, medical, medical residencies, business administration and public policy degrees, post-doctoral positions …
  • CH2M HILL Companies, Ltd.:戦略・SWOT・企業財務分析
    CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • TYI 2011 Ltd:企業の戦略的SWOT分析
    TYI 2011 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kuwait Energy Plc:企業の戦略的SWOT分析
    Kuwait Energy Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Neptune Technologies & Bioressources Inc:企業のM&A・事業提携・投資動向
    Neptune Technologies & Bioressources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Neptune Technologies & Bioressources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed …
  • Redbiotec AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Redbiotec AG (Redbiotec) is a biopharmaceutical company that develops prophylactic vaccines, which target various virus associated diseases. The company produces multi component virus like particles and other protein assemblies through its rePAX coexpression technology. It is developing prod …
  • OSI Systems Inc (OSIS):企業の財務・戦略的SWOT分析
    OSI Systems Inc (OSIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Quest Diagnostics Inc (DGX):企業の財務・戦略的SWOT分析
    Quest Diagnostics Inc (DGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Allscripts Healthcare Solutions, Inc.:企業のM&A・事業提携・投資動向
    Allscripts Healthcare Solutions, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allscripts Healthcare Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • William Demant Holding AS (WDH)-医療機器分野:企業M&A・提携分析
    Summary William Demant Holding A/S (WDH) develops, manufactures and distributes products and equipment designed to aid people with hearing loss in their individual communication. Its major areas of focus include hearing devices, hearing implants, diagnostic instruments and personal communication dev …
  • Stratasys Ltd.:戦略・SWOT・企業財務分析
    Stratasys Ltd. - Strategy, SWOT and Corporate Finance Report Summary Stratasys Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Autoliv, Inc.:企業の戦略・SWOT・財務分析
    Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report Summary Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Paddy Power Betfair Plc:企業の戦略・SWOT・財務分析
    Paddy Power Betfair Plc - Strategy, SWOT and Corporate Finance Report Summary Paddy Power Betfair Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆